EMA Authorised: Myclausen (mycophenolate mofetil) — Passauer Pharma GmbH

View source ↗

Summary

EMA authorised the drug Myclausen (mycophenolate mofetil) by Passauer Pharma GmbH. It is indicated for graft rejection in transplant patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection

Drugs mentioned

• Myclausen (mycophenolate mofetil)

Snippet

Status: Authorised. Therapeutic area: Graft Rejection. MAH: Passauer Pharma GmbH. Decision date: 26/03/2026